Lack of Association of Antihypertensive Drugs with the Risk and Severity of COVID-19: A Meta-Analysis

Autor: James L. Overton, Nipavan Chiamvimonvat, Phung N. Thai, Lu Ren, Shandong Yu, Wilson Xu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Adrenergic beta-Antagonists
MEDLINE
Angiotensin II Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
030204 cardiovascular system & hematology
Cochrane Library
Cardiorespiratory Medicine and Haematology
Cardiovascular
03 medical and health sciences
Angiotensin Receptor Antagonists
0302 clinical medicine
Internal medicine
Medicine
Humans
Severe acute respiratory syndrome coronavirus 2
030212 general & internal medicine
Diuretics
Antihypertensive drugs
Antihypertensive Agents
business.industry
SARS-CoV-2
COVID-19
coronavirus 2
Odds ratio
Calcium Channel Blockers
Confidence interval
COVID-19 Drug Treatment
Meta-analysis
Good Health and Well Being
Severe acute respiratory syndrome
Cardiovascular System & Hematology
Case-Control Studies
Hypertension
Cardiology
Original Article
business
Cardiology and Cardiovascular Medicine
Cohort study
Zdroj: Journal of Cardiology
Journal of cardiology, vol 77, iss 5
ISSN: 1876-4738
0914-5087
Popis: Highlights • The usage of antihypertensive drugs is not associated with the risk and severity of COVID-19. • Hypertensive patients with COVID-19 benefit from prior usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.
Background The association of antihypertensive drugs with the risk and severity of COVID-19 remains unknown. Methods and Results We systematically searched PubMed, MEDLINE, The Cochrane Library, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, and medRxiv for publications before July 13, 2020. Cohort studies and case-control studies that contain information on the association of antihypertensive agents including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), calcium-channel blockers (CCBs), β-blockers, and diuretics with the risk and severity of COVID-19 were selected. The random-effects or fixed-effects models were used to pool the odds ratio (OR) with 95% confidence interval (CI) for the outcomes. The literature search yielded 53 studies that satisfied our inclusion criteria, which comprised 39 cohort studies and 14 case-control studies. These studies included a total of 2,100,587 participants. We observed no association between prior usage of antihypertensive medications including ACEIs/ARBs, CCBs, β-blockers, or diuretics and the risk and severity of COVID-19. Additionally, when only hypertensive patients were included, the severity and mortality were lower with prior usage of ACEIs/ARBs (overall OR of 0.81, 95% CI 0.66-0.99, p
Databáze: OpenAIRE
Externí odkaz: